secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001193125-25-233983
Event type: debt
Sentiment:  negative
Materiality: 0.95
Item codes: 1.01, 2.02, 2.03, 3.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KPTI closes $67.5M debt package, note exchanges & $8.75M equity; runway into Q2 2026
--------------------------------------------------------------------------------

- $27.5M new term loan (SOFR+10.25%), $25M interest/royalty deferrals, $15M liquidity covenant relief.
- Exchanged $15M 2029 notes for new 9% 2028 notes and $24.25M Oct 2025 notes for stock & warrants.
- Raised $8.75M via private placement of 7.2M shares and warrants at $6.64 exercise price.
- Pro forma cash ~$36M; shares outstanding ~15.9M; total debt $112.5M term loan, $15M+$103.5M convert notes.
- Lenders get board observer; interest payments paid-in-kind through March 2026, cash starts June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312525233983/0001193125-25-233983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312525233983/d940170d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-233983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer